Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas

NCT04305444 is registered in ClinicalTrials.gov with Zhejiang DTRM Biopharma as lead sponsor.

NCT NCT04305444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04305444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Lead sponsor
Zhejiang DTRM Biopharma
Phase
Phase 2
Overall status
Terminated
Start date
April 24, 2020
Completion date
December 31, 2024
Enrollment
55 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma, refractory chronic lymphocytic leukemia, relapsed chronic lymphocytic leukemia, richter's transformation